RxDoctor Payments Data

Lia Miceli, MD

Urogynecology and Reconstructive Pelvic Surgery · Pittsburgh, PANPI 1962931170

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (57.0%), travel and lodging and education — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Boston Scientific at 43.7% of the total. Reporting peaked in 2024 at $1,945 and has fallen 75.6% since, to $474 in 2025.

$4,787in general payments, 2019–2025

Across 50 payments — averaging $95.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Axonics, Inc.$1K
  • Medtronic$597
  • Medical Device Business Services, Inc.$325
  • Coloplast$193
  • Sumitomo Pharma America, Inc.$44
  • plus $112 from 4 others

What the payments were for

  • Travel & lodging$1,52932%
  • Food & beverage$2,72757%
  • Education$53011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,787 in reported general payments places this provider in the 65th percentile of 51 urogynecology and reconstructive pelvic surgery providers in Pennsylvania.

See all urogynecology and reconstructive pelvic surgery providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$6,780
Medicare patients
22
Services billed
185

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron36$17,187
Estradiol43$2,941
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst21$245
Ibuprofen13$52
Tramadol Hcl14$17

Paid to pharmacies, not to this prescriber.

Other urogynecology and reconstructive pelvic surgery in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →